140 related articles for article (PubMed ID: 11240036)
1. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies.
Cavanna B; Jiang H; Allaria S; Carpo M; Scarlato G; Nobile-Orazio E
J Neuroimmunol; 2001 Mar; 114(1-2):226-31. PubMed ID: 11240036
[TBL] [Abstract][Full Text] [Related]
2. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line.
Cavanna B; Carpo M; Pedotti R; Scarpini E; Meucci N; Allaria S; Scarlato G; Nobile-Orazio E
J Neuroimmunol; 1999 Feb; 94(1-2):157-64. PubMed ID: 10376949
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
[TBL] [Abstract][Full Text] [Related]
4. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies.
Nobile-Orazio E; Giannotta C; Briani C
J Neuroimmunol; 2010 Feb; 219(1-2):119-22. PubMed ID: 20006388
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies.
O'Hanlon GM; Veitch J; Gallardo E; Illa I; Chancellor AM; Willison HJ
Autoimmunity; 2000 Sep; 32(2):133-44. PubMed ID: 11078160
[TBL] [Abstract][Full Text] [Related]
6. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
[TBL] [Abstract][Full Text] [Related]
7. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2.
Wu X; Okada N; Momota H; Irie RF; Okada H
J Immunol; 1999 Jan; 162(1):533-9. PubMed ID: 9886430
[TBL] [Abstract][Full Text] [Related]
8. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
9. Detection of serum anti-ganglioside antibodies by latex agglutination assay in Guillain-Barré syndrome: comparison with ELISA.
Irie S; Saito T; Kanazawa N; Ogino M; Ogino Y; Sakai F
Intern Med; 2003 Jun; 42(6):490-5. PubMed ID: 12857046
[TBL] [Abstract][Full Text] [Related]
10. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset.
Budding K; Bos JW; Dijkxhoorn K; de Zeeuw E; Bloemenkamp LM; Zekveld EM; Groen EJN; Jacobs BC; Huizinga R; Goedee HS; Cats EA; Leusen JHW; van den Berg LH; Hack CE; van der Pol WL
J Neuroinflammation; 2024 Apr; 21(1):100. PubMed ID: 38632654
[TBL] [Abstract][Full Text] [Related]
11. [Guillain-Barré syndrome with high titers of anti-GM2 and anti-GalNAc-GD1a antibody following cytomegalovirus hepatitis].
Shimoya K; Ohnishi A; Hashimoto T; Yuki N
Rinsho Shinkeigaku; 1997 Feb; 37(2):106-10. PubMed ID: 9164140
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies.
Sudo M; Miyaji K; Späth PJ; Morita-Matsumoto K; Yamaguchi Y; Yuki N
Int Immunopharmacol; 2016 Nov; 40():11-15. PubMed ID: 27567246
[TBL] [Abstract][Full Text] [Related]
13. The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients.
Wu X; Okada N; Goto M; Iwamoto A; Okada H
Microbiol Immunol; 2000; 44(5):405-10. PubMed ID: 10888361
[TBL] [Abstract][Full Text] [Related]
14. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection.
Irie S; Saito T; Nakamura K; Kanazawa N; Ogino M; Nukazawa T; Ito H; Tamai Y; Kowa H
J Neuroimmunol; 1996 Aug; 68(1-2):19-26. PubMed ID: 8784256
[TBL] [Abstract][Full Text] [Related]
15. Acute cytomegalovirus infection and IgM anti-GM2 antibody.
Yuki N; Tagawa Y
J Neurol Sci; 1998 Jan; 154(1):14-7. PubMed ID: 9543317
[TBL] [Abstract][Full Text] [Related]
16. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
Takahashi T; Johnson TD; Nishinaka Y; Morton DL; Irie RF
J Invest Dermatol; 1999 Feb; 112(2):205-9. PubMed ID: 9989797
[TBL] [Abstract][Full Text] [Related]
17. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
18. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay.
Alaedini A; Briani C; Wirguin I; Siciliano G; D'Avino C; Latov N
J Neurol Sci; 2002 Apr; 196(1-2):41-4. PubMed ID: 11959155
[TBL] [Abstract][Full Text] [Related]
19. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?
Nobile-Orazio E; Gallia F; Terenghi F; Allaria S; Giannotta C; Carpo M
J Neurol Sci; 2008 Mar; 266(1-2):156-63. PubMed ID: 17915254
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.
Ang CW; Jacobs BC; Brandenburg AH; Laman JD; van der Meché FG; Osterhaus AD; van Doorn PA
Neurology; 2000 Apr; 54(7):1453-8. PubMed ID: 10751257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
